FDA
-
-
-
-
-
-
-
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cardiff Oncology (CRDF)
-
-
-
-
-
-
-
Cardiff Oncology presents leukemia trial data at ASH 2025
-
-
-
-
-
-
-
Cardiff Oncology (CRDF) Appoints Roger Sidhu as Chief Medical Officer, Announces Timing for the Next Update from the CRDF-004 Trial
-
-
-
-
-
-
-
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
-
-
-
-
-
-
-
Cardiff Oncology (CRDF) Announces Positive Initial Data from First-line RAS-mutated mCRC Clinical Trial
-
-
-
-
-
-
-
Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update
-
322,086 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

